We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New Horizons in the Treatment of Corneal Endothelial Dysfunction.
- Authors
Rocha-de-Lossada, Carlos; Rachwani-Anil, Rahul; Borroni, Davide; Sánchez-González, José-María; Esteves-Marques, Raquel; Soler-Ferrández, Fernando-Luis; Gegúndez-Fernández, Jose-Antonio; Romano, Vito; Livny, Eitan; Rodríguez Calvo-de-Mora, Marina
- Abstract
The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.
- Subjects
CORNEA surgery; ENDOTHELIAL cells; ENDOTHELIUM; CORNEA diseases; CELLULAR therapy; TREATMENT effectiveness; CORNEAL transplantation; GENE therapy; DISEASE management; TRANSPLANTATION of organs, tissues, etc.
- Publication
Journal of Ophthalmology, 2021, p1
- ISSN
2090-004X
- Publication type
Article
- DOI
10.1155/2021/6644114